Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 5:20 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1993–2016 of 33,121 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: placebo Clear all
Not listed Not applicable Interventional Accepts healthy volunteers

Determination of the Safety and Efficacy of a Novel Oral Rinse on Oral Health

NCT04197427
View directory record Official record
Conditions
Plaque, Gingivitis
Interventions
Experimental Oral Rinse, Placebo
Device
Lead sponsor
You First Services
Industry
Eligibility
18 Years to 75 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Nov 1, 2026, 5:20 AM EST
Completed Phase 4 Interventional Results available

Corticosteroid Pulse After Ablation

NCT00807586
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Solumedrol, Placebo
Drug
Lead sponsor
Minneapolis Heart Institute Foundation
Other
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Nov 1, 2026, 5:20 AM EST
Completed Phase 2 Interventional Results available

A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)

NCT04771273
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis (NASH)
Interventions
Survodutide, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
36
States / cities
Huntsville, Alabama • Coronado, California • Huntington Park, California + 31 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Nov 1, 2026, 5:20 AM EST
Completed Early Phase 1 Interventional

Curcumin in Rheumatoid Arthritis

NCT00752154
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Curcumin (Longvida™)
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Beverly Hills, California • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 29, 2023 · Synced Nov 1, 2026, 5:20 AM EST
Completed Phase 3 Interventional Results available

Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)

NCT01715805
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Cariprazine, Placebo, Antidepressant Therapy (ADT)
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,022 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
83
States / cities
Tucson, Arizona • Little Rock, Arkansas • Cerritos, California + 68 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Nov 1, 2026, 5:20 AM EST
Completed Phase 2 Interventional Results available

A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)

NCT05323656
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
Setanaxib, Pembrolizumab, Placebo
Drug · Biological
Lead sponsor
Calliditas Therapeutics Suisse SA
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
5
States / cities
Miami Beach, Florida • City of Saint Peters, Missouri • Creve Coeur, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Nov 1, 2026, 5:20 AM EST
Terminated Phase 1 Interventional Accepts healthy volunteers

Oxytocin Aging Study

NCT02069431
View directory record Official record
Conditions
Inflammation
Interventions
Intranasal Oxytocin spray, Intranasal Placebo spray
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
55 Years to 100 Years
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
2
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 19, 2020 · Synced Nov 1, 2026, 5:20 AM EST
Completed Phase 1Phase 2 Interventional Results available

Fecal Microbiota Transplant (FMT) in Pediatric Active Ulcerative Colitis and Pediatric Active Crohn's Colitis

NCT02330653
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease
Interventions
Fecal Microbiota Transplant (FMT), Placebo
Biological
Lead sponsor
Stacy A. Kahn
Other
Eligibility
5 Years to 30 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Nov 1, 2026, 5:20 AM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Biology and Experience of Eating in Women With Obesity

NCT02805972
View directory record Official record
Conditions
Obesity
Interventions
Naloxone, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Nov 1, 2026, 5:20 AM EST
Completed Phase 2 Interventional Results available

A Long Term Extension of Study NC19453 Evaluating Safety and Efficacy of RO4607381

NCT00400439
View directory record Official record
Conditions
Coronary Heart Disease
Interventions
dalcetrapib (RO4607381), placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
9
States / cities
Indianapolis, Indiana • Iowa City, Iowa • Louisville, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2020 · Synced Nov 1, 2026, 5:20 AM EST
Completed Phase 1 Interventional

Staccato Loxapine Multidose PK

NCT00555412
View directory record Official record
Conditions
Volunteers on Chronic, Stable Antipsychotic Regimens
Interventions
A - 10 mg loxapine q 4 h x 3 (30 mg total), B - 10 mg x 1, 5 mg x 2 loxapine q 4 h (20 mg total), C - 5 mg loxapine q 4 h x 3 (15 mg total), D - inhaled placebo q 4 h x 3
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Nov 1, 2026, 5:20 AM EST
Completed Phase 2 Interventional Results available

Pilot Study Testing the Effect of Ivacaftor on Lung Function in Subjects With Cystic Fibrosis and Residual CFTR Function

NCT01685801
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ivacaftor, Placebo-matched-to-ivacaftor tablet
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 19, 2015 · Synced Nov 1, 2026, 5:20 AM EST
Completed Phase 2 Interventional Results available

Anti-Inflammatory Small Drug Adjunctive Therapy for Type 2 Diabetes

NCT02597101
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Insulin Resistance
Interventions
Metformin, saxagliptin, AZD9668, placebo
Drug
Lead sponsor
Nick Giannoukakis, PhD
Other
Eligibility
21 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Nov 1, 2026, 5:20 AM EST
Terminated Phase 4 Interventional Results available

Effects of Atorvastatin on Myonecrosis

NCT00344019
View directory record Official record
Conditions
Coronary Disease
Interventions
Placebo Oral Tablet, Atorvastatin 80mg, Screening
Drug · Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 2, 2018 · Synced Nov 1, 2026, 5:20 AM EST
Completed Not applicable Interventional Results available

Comparison of Fluoxetine, Calcium and Placebo for the Treatment of Moderate to Severe Premenstrual Syndrome (PMS)

NCT00965562
View directory record Official record
Conditions
Premenstrual Syndrome
Interventions
Fluoxetine, Calcium, Placebo
Drug
Lead sponsor
Donaghue Medical Research Foundation
Other
Eligibility
18 Years to 48 Years · Female only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 23, 2015 · Synced Nov 1, 2026, 5:20 AM EST
Terminated Phase 2 Interventional

Effects of Pycnogenol on Cardiac Fibrosis and Diastolic Dysfunction in Aged Hypertensive Subjects

NCT00952627
View directory record Official record
Conditions
Cardiac Fibrosis, Diastolic Dysfunction
Interventions
Pycnogenol, Placebo
Dietary Supplement
Lead sponsor
University of Arizona
Other
Eligibility
50 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Nov 1, 2026, 5:20 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Adhesion Quality and Irritation of an Alternate Second Generation Estradiol Transdermal System

NCT00650442
View directory record Official record
Conditions
Healthy
Interventions
Estradiol Transdermal System Placebo - Alternate Adhesive, Estradiol Transdermal System Placebo - Current Adhesive
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
40 Years to 66 Years · Female only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 1, 2008 · Synced Nov 1, 2026, 5:20 AM EST
Completed Phase 1 Interventional

A Study to Evaluate SIMPONI (Golimumab) Therapy in Children, Adolescents and Young Adults With Pre-Symptomatic Type 1 Diabetes

NCT03298542
View directory record Official record
Conditions
Pre-Symptomatic Type 1 Diabetes
Interventions
Golimumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
6 Years to 21 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
3
States / cities
Aurora, Colorado • Philadelphia, Pennsylvania • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Nov 1, 2026, 5:20 AM EST
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Research Study to Evaluate the Safety of NNC4004-0002 When Given to Participants With Asymptomatic Hyperuricemia

NCT06859073
View directory record Official record
Conditions
Healthy Volunteers, Hyperuricemia
Interventions
NNC4004-0002, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
35 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Nov 1, 2026, 5:20 AM EST
Terminated Not applicable Interventional

Infantile Colic: Study of the Efficacy of Lactobacillus GG (ATCC 53103) Plus Chamomile in Breastfeeding Infants

NCT03477669
View directory record Official record
Conditions
Infantile Colic
Interventions
chamomile/probiotic arm, Placebo of chamomile/probiotic arm
Dietary Supplement
Lead sponsor
University of Nebraska
Other
Eligibility
3 Weeks to 16 Weeks
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 25, 2023 · Synced Nov 1, 2026, 5:20 AM EST
Completed Phase 2 Interventional Accepts healthy volunteers

Protective Effects of EPI-743 on Noise-Induced Hearing Loss

NCT02257983
View directory record Official record
Conditions
Noise-induced Hearing Loss
Interventions
EPI-743, Placebo
Drug
Lead sponsor
Edison Pharmaceuticals Inc
Industry
Eligibility
18 Years to 30 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 18, 2020 · Synced Nov 1, 2026, 5:20 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Tolerability Study of Xisomab 3G3 in Healthy Adult Subjects

NCT03097341
View directory record Official record
Conditions
Thrombosis
Interventions
xisomab 3G3- Dose 1, xisomab 3G3-Dose 2, xisomab 3G3-Dose 3, xisomab 3G3- Dose 4, Placebo
Drug · Other
Lead sponsor
Aronora, Inc.
Industry
Eligibility
18 Years to 48 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 5, 2019 · Synced Nov 1, 2026, 5:20 AM EST
Completed Phase 2 Interventional

A Single-Center, Randomized, Double-Masked, Placebo and Active Controlled, Dose-Ranging Evaluation of the Duration of Action of Brimonidine Tartrate Ophthalmic Solution in the Control of Ocular Redness Induced by Conjunctival Allergen Challenge (CAC)

NCT01275105
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Vehicle, Brimonidine Tartrate 0.01%, Brimonidine Tartrate 0.025%, Oxymetazoline HCl 0.025%
Drug
Lead sponsor
Eye Therapies, LLC
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 6, 2012 · Synced Nov 1, 2026, 5:20 AM EST
Completed Phase 1 Interventional

A Study to Assess the Effect of AZD5634 on Mucociliary Clearance, Safety, Tolerability and Pharmacokinetic Parameters in Patients With Cystic Fibrosis

NCT02950805
View directory record Official record
Conditions
Pulmonary/Respiratory Diseases
Interventions
Placebo, AZD5634
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 60 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Birmingham, Alabama • Baltimore, Maryland • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 13, 2018 · Synced Nov 1, 2026, 5:20 AM EST